VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYNE VYNE Therapeutics Inc.

Market Closed 06-26 16:00:00 EDT

0.6483

-0.0034

-0.52%

盘后0.6437

-0.0046-0.71%

17:32 EDT

High0.6615	Low0.6236	Vol120.32K
Open0.6324	D1 Closing0.6517	Amplitude5.81%
Mkt Cap21.58M	Tradable Cap19.98M	Total Shares33.29M
T/O78.29K	T/O Rate0.39%	Tradable Shares30.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYNE","market":"US","secType":"STK","nameCN":"VYNE Therapeutics Inc.","latestPrice":0.6483,"timestamp":1782504000000,"preClose":0.6517,"halted":0,"volume":120322,"hourTrading":{"tag":"盘后","latestPrice":0.6437,"preClose":0.6483,"latestTime":"17:32 EDT","volume":545,"amount":357.6821,"timestamp":1782509579346,"change":-0.0046,"changeRate":-0.007095,"amplitude":0.025143},"delay":0,"changeRate":-0.0052171244437624045,"floatShares":30823100,"shares":33286422,"eps":-0.501428,"marketStatus":"Market Closed","change":-0.0034,"latestTime":"06-26 16:00:00 EDT","open":0.6324,"high":0.6615,"low":0.62361,"amount":78290.65331386,"amplitude":0.05814,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.501428,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":0.6517,"preHourTrading":{"tag":"盘前","latestPrice":0.63,"preClose":0.6517,"latestTime":"07:02 EDT","volume":48,"amount":30.30509952,"timestamp":1782471775152,"change":-0.0217,"changeRate":-0.033298,"amplitude":0.033298},"postHourTrading":{"tag":"盘后","latestPrice":0.6437,"preClose":0.6483,"latestTime":"17:32 EDT","volume":545,"amount":357.6821,"timestamp":1782509579346,"change":-0.0046,"changeRate":-0.007095,"amplitude":0.025143},"volumeRatio":0.999416904833238,"impliedVol":3.8705,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VYNE","defaultTab":"news","newsList":[{"id":"2640943754","title":"Vyne Therapeutics publishes investor presentation on Yarrow Bioscience, YB-101 anti-TSHR program for Graves' disease, thyroid eye disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943754?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:00","pubTimestamp":1780405215,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics publishes investor presentation on Yarrow Bioscience, YB-101 anti-TSHR program for Graves' disease, thyroid eye disease. Vyne investor deck outlined a planned reverse merger with Yarrow Bioscience, with a Q3 2026 expected close.Combined company expected to trade on NASDAQ under ticker YARW.Yarrow’s lead program YB-101, an anti-TSHR antibody for Graves’ disease and thyroid eye disease, set to start a Phase 2a/2b trial in Q2 2026.Phase 2a proof-of-concept data in Graves’ disease targeted for 2H 2027; Phase 2b portion planned to begin in H1 2028.$200 million raised to date, including an expected $100 million pre-closing financing; cash runway projected into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL3XtLFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363982","title":"VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637363982?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:51","pubTimestamp":1779407503,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics ( ($VYNE) ) has shared an announcement. On May 21, 2026, Yarrow Bioscience published an investor presentation outlining its strat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vyne-highlights-yarrow-merger-strategy-and-endocrine-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vyne-highlights-yarrow-merger-strategy-and-endocrine-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637573503","title":"Vyne Therapeutics publishes Yarrow Bioscience investor presentation factsheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2637573503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637573503?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:05","pubTimestamp":1779397547,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics published the “Yarrow Bioscience Investor Presentation” dated May 21, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLwPXMk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635055880","title":"VYNE Therapeutics Q1 EPS $(0.08) Beats $(0.18) Estimate, Sales $86.000K Miss $200.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635055880","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635055880?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:14","pubTimestamp":1778883267,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.18) by 55.56 percent. This is a 60 percent increase over losses of $(0.20) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52620182/vyne-therapeutics-q1-eps-0-08-beats-0-18-estimate-sales-86-000k-miss-200-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"VYNE Therapeutics Q1 EPS $(0.08) Beats $(0.18) Estimate, Sales $86.000K Miss $200.000K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037914","title":"Vyne Therapeutics Q1 FY26 net loss narrows 58.4% to $3.59 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037914","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037914?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:08","pubTimestamp":1778875681,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics reported Q1 net loss of USD 3.59 million, narrowing 58.4% from year-ago period.Revenue fell 57.4% to USD 86,000, reflecting lower royalty revenue from LEO Pharma sales of Finacea foam.Operating loss narrowed 58.5% to USD 3.82 million as research and development expense dropped 86.7% to USD 817,000.Cash, cash equivalents, and marketable securities totaled USD 24.9 million at March 31; net cash used in operating activities improved to USD 4.08 million from USD 11.46 million a year earlier.Company reaffirmed expectation to close merger with Yarrow Biosciences in Q3 2026, with a pre-closing special cash dividend expected to total about USD 14.5 million to USD 16.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4PCGdc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632956809","title":"Vyne Therapeutics Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632956809","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632956809?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:21","pubTimestamp":1777900865,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc  expected to post a loss of18cents a share - Earnings Preview Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to  show a fall in quarterly revenue when it reports  results on Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H1AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618908487","title":"VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2618908487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618908487?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:04","pubTimestamp":1773277464,"startTime":"0","endTime":"0","summary":"The latest update is out from VYNE Therapeutics ( ($VYNE) ). On September 12, 2025, VYNE Therapeutics disclosed that it had fallen out of complianc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-granted-nasdaq-extension-to-regain-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-granted-nasdaq-extension-to-regain-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VYNE","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618308976","title":"Nasdaq Grants Vyne Therapeutics Extension to Regain $1 Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2618308976","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618308976?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:58","pubTimestamp":1773262716,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics said it received a Nasdaq notice that it failed to regain compliance with the exchange’s $1.00 minimum bid price requirement by the initial March 10, 2026 deadline. Nasdaq granted the company an additional 180-day extension until Sept. 7, 2026 to regain compliance, and the stock will continue trading on the Nasdaq Capital Market in the meantime. Vyne said it may pursue options including a reverse stock split to cure the deficiency.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLy9V1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616556079","title":"Vyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2616556079","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616556079?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:32","pubTimestamp":1772634752,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryVyne Therapeutics Inc VYNE.OQ reported a quarterly adjusted loss of 11 cents per share for the quarter ended D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL8N3ZS1U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616330085","title":"Vyne Therapeutics Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330085","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330085?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:55","pubTimestamp":1772459705,"startTime":"0","endTime":"0","summary":"Vyne Therapeutics Inc  expected to post a loss of18cents a share - Earnings Preview Vyne Therapeutics Inc VYNE.OQ VYNE.O is expected to  show a fall in quarterly revenue when it reports  results on Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL8N3ZQ1WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614552958","title":"VYNE FY 2025 R&D expenses fall 37.8% to USD 19.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614552958","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614552958?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:02","pubTimestamp":1772197357,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDLbLbfRw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607245180","title":"VYNE Therapeutics Amends Merger Terms with Yarrow Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2607245180","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607245180?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:32","pubTimestamp":1769808721,"startTime":"0","endTime":"0","summary":"The latest update is out from VYNE Therapeutics ( ($VYNE) ). On January 30, 2026, VYNE Therapeutics, its wholly owned subsidiary Yarrow Merger Sub ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-amends-merger-terms-with-yarrow-bioscience?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vyne-therapeutics-amends-merger-terms-with-yarrow-bioscience?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607021694","title":"Vyne Therapeutics Amends Merger Agreement With Yarrow Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2607021694","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607021694?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:11","pubTimestamp":1769807502,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics Inc. has entered into an amendment to its agreement with Yarrow Bioscience, Inc. and Yarrow Merger Sub Corp. The amendment allows VYNE to provide certain pre-funded warrants to Yarrow stockholders who, under the exchange ratio, would otherwise exceed a set beneficial ownership limitation. These pre-funded warrants will permit holders to purchase shares of VYNE common stock equal to the excess entitlement. The update also clarifies that the Parent Pre-Closing Dividend may be awarded to holders of VYNE common stock and shares underlying certain outstanding VYNE warrants as of the record date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL9yj9MN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592990133","title":"Vyne Therapeutics and Yarrow Bioscience announce merger in all-stock deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990133","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990133?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976479,"startTime":"0","endTime":"0","summary":"VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. have entered into a definitive agreement to combine in an all-stock transaction. Upon completion, the combined company will operate as Yarrow Bioscience, Inc. and will be listed on Nasdaq under the ticker symbol \"YARW.\" The newly formed company will focus on advancing YB-101 , a clinical-stage TSHR antibody being developed for the treatment of Graves' disease  and thyroid eye disease . Pre-closing private financings totaling approximately $200 million are expected to fund operations into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 17, 2025, and is solely respon","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL6q19qh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","SG9999014013.SGD","NDAQ","SG9999014039.USD","VYNE","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4007","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592990966","title":"Vyne Therapeutics - to Declare Cash Dividend to Pre-Merger Vyne Stockholders of $14.5 Mln-$16.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990966?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5SBJDQ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592990624","title":"Vyne Therapeutics Inc - Combined Company to Trade Under Ticker 'Yarw'","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990624?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5SBJDQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592906469","title":"Vyne Therapeutics Inc - Pre-Closing Financings of $200 Mln to Fund Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906469?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5SBJDQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592906199","title":"Vyne Therapeutics Inc - Combined Company to Be Named Yarrow Bioscience, Led by Rebecca Frey","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906199","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906199?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA5SBJDQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VYNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592918981","title":"VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918981","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918981?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:00","pubTimestamp":1765976400,"startTime":"0","endTime":"0","summary":"Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3206928/0/en/VYNE-Therapeutics-and-Yarrow-Bioscience-Announce-Merger-Agreement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHR","BK4588","BK4173","BK4187","BK4585","LU0170899867.USD","VYNE","BK4007","GD","BK4550","BK4566","YB","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592990892","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990892","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990892?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:55","pubTimestamp":1765976100,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nAQN2LDY7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYNE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vynetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":-0.0465},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1026},{"period":"1year","weight":-0.5998},{"period":"ytd","weight":0.1176}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.037101},{"month":2,"riseRate":0.444444,"avgChangeRate":0.014686},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.004341},{"month":4,"riseRate":0.222222,"avgChangeRate":-0.154087},{"month":5,"riseRate":0.555556,"avgChangeRate":0.00572},{"month":6,"riseRate":0.111111,"avgChangeRate":-0.050866},{"month":7,"riseRate":0.375,"avgChangeRate":-0.153902},{"month":8,"riseRate":0.125,"avgChangeRate":-0.085706},{"month":9,"riseRate":0.5,"avgChangeRate":-0.023153},{"month":10,"riseRate":0.5,"avgChangeRate":0.011012},{"month":11,"riseRate":0.5,"avgChangeRate":-0.029442},{"month":12,"riseRate":0.375,"avgChangeRate":-0.029662}],"exchange":"NASDAQ","name":"VYNE Therapeutics Inc.","nameEN":"VYNE Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VYNE Therapeutics Inc.,VYNE,VYNE Therapeutics Inc.股票,VYNE Therapeutics Inc.股票老虎,VYNE Therapeutics Inc.股票老虎国际,VYNE Therapeutics Inc.行情,VYNE Therapeutics Inc.股票行情,VYNE Therapeutics Inc.股价,VYNE Therapeutics Inc.股市,VYNE Therapeutics Inc.股票价格,VYNE Therapeutics Inc.股票交易,VYNE Therapeutics Inc.股票购买,VYNE Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VYNE Therapeutics Inc.(VYNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VYNE Therapeutics Inc.(VYNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}